The Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Closer Look at the 2022 ACC Expert Consensus Decision Pathway
The Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Closer Look at the 2022 ACC Expert Consensus Decision Pathway is organized by Pri-Med.
Release Date: 08/9/2023
Expiration Date: 08/9/2024
Description:
This program is designed to improve health care providers' knowledge and competence about available lipid-lowering medications and how to use these agents to narrow the treatment gap and improve outcomes in patients with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD).
Learning Objectives:
• Identify factors that lead to poor statin adherence and relevant management strategies
• Summarize data supporting residual ASCVD risk in statin patients unable to reach LDL-C goals
• Apply the clinical trial data and guidelines for the use of nonstatin treatments in patients with ASCVD and HeFH
• Consider clinical characteristics and preferences in order to select the most appropriate non-statin therapies in the management of patients with residual hypercholesterolemia